{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:46:42Z","timestamp":1792504002435,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2026.01.012","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:11:05Z","timestamp":1772885465000},"page":"543-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9015-7997","authenticated-orcid":false,"given":"Stuart Keith","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-4930","authenticated-orcid":false,"given":"Luis Antonio","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-2064","authenticated-orcid":false,"given":"Marlen Ivon","family":"Castellanos-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cld.2026.01.012_bib1","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/jgh.15009","article-title":"Nonalcoholic fatty liver disease burden: australia, 2019-2030","volume":"35","author":"Adams","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.012_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/ueg2.70072","article-title":"The rising Global Burden of MASLD and other metabolic diseases (2000-2021)","author":"Danpanichkul","year":"2025","journal-title":"United Eur Gastroenterol J"},{"issue":"3","key":"10.1016\/j.cld.2026.01.012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101175","article-title":"The burden of liver disease in Latin America","volume":"29","author":"D\u00edaz","year":"2024","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2026.01.012_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.01.012_bib5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2026.01.012_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5694\/mja2.51096","article-title":"Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study","volume":"215","author":"Roberts","year":"2021","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.cld.2026.01.012_bib8","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41598-022-05168-0","article-title":"A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab study","volume":"12","author":"Farrell","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cld.2026.01.012_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2026.01.012_bib10","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/jgh.16314","article-title":"Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle","volume":"38","author":"Vaz","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.012_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/liv.15725","article-title":"Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage","volume":"44","author":"Clayton-Chubb","year":"2024","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.cld.2026.01.012_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30426","article-title":"Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease","volume":"5","author":"Chhatwal","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.cld.2026.01.012_bib13","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/geront\/gnaa032","article-title":"Aging in New Zealand: ka haere ki te ao pakeketanga","volume":"60","author":"Parr-Brownlie","year":"2020","journal-title":"Gerontol"},{"key":"10.1016\/j.cld.2026.01.012_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eclinm.2019.05.007","article-title":"Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians","volume":"11","author":"Powell","year":"2019","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cld.2026.01.012_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwaf135","article-title":"A scoping review on cardiometabolic risk factors among Pacific Island populations and implications on future research in the region","author":"Paulino","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.cld.2026.01.012_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002275","article-title":"CREBRF missense variant rs373863828 has both direct and indirect effects on type 2 diabetes and fasting glucose in Polynesian peoples living in Samoa and Aotearoa New Zealand","volume":"10","author":"Russell","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"10.1016\/j.cld.2026.01.012_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009273","article-title":"The impact of global and local Polynesian genetic ancestry on complex traits in Native Hawaiians","volume":"17","author":"Sun","year":"2021","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.cld.2026.01.012_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12889-018-5511-9","article-title":"Longitudinal study of health, disease and access to care in rural Victoria: the Crossroads-II study: methods","volume":"18","author":"Glenister","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cld.2026.01.012_bib19","doi-asserted-by":"crossref","DOI":"10.5694\/mja2.70008","article-title":"Recommendations for the assessment of metabolic dysfunction-associated fatty liver disease (MAFLD) in primary care: a consensus statement","author":"Adams","year":"2025","journal-title":"Med J Aust"},{"key":"10.1016\/j.cld.2026.01.012_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/nu14214557","article-title":"Trends and factors associated with obesity prevalence in rural Australian adults-comparative analysis of the CrossRoads studies in Victoria over 15 years","volume":"14","author":"Hannah","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.cld.2026.01.012_bib21","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/jgh.16314","article-title":"NAFLD prevalence in Australia has risen over 15-years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle","volume":"38","author":"Vaz","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.01.012_bib22","article-title":"The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease","volume":"15","author":"D\u00edaz","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2026.01.012_bib23","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.012_bib25","series-title":"Health and Independence report","year":"2024"},{"issue":"3","key":"10.1016\/j.cld.2026.01.012_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.102495","article-title":"Global epidemiology and implications of PNPLA3 I148M variant in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"15","author":"Souza","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.cld.2026.01.012_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2025.04.035","article-title":"High inherited risk predicts age-associated increases in fibrosis in patients with MASLD","author":"D\u00edaz","year":"2025","journal-title":"J Hepatol"},{"issue":"21","key":"10.1016\/j.cld.2026.01.012_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162513","article-title":"Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease","volume":"132","author":"Tamaki","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.cld.2026.01.012_bib30","article-title":"Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group","volume":"13","author":"Diaz","year":"2025","journal-title":"Ann Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2026.01.012_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.numecd.2023.07.040","article-title":"Association between urbanization and metabolic syndrome in low- and middle-income countries: a systematic review and meta-analysis","volume":"34","author":"Nsabimana","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cld.2026.01.012_bib32","series-title":"Progress in universal health in the Americas: addressing unmet healthcare needs, gaps in coverage, and lack of financial protection through primary health care","year":"2024"},{"issue":"2","key":"10.1016\/j.cld.2026.01.012_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/mja2.52189","article-title":"Steatotic liver disease in rural and regional Victoria, according to the NAFLD and newer diagnostic criteria: retrospective cohort analyses of 2001-03 and 2016-18 data","volume":"220","author":"Vaz","year":"2024","journal-title":"Med J Aust"},{"key":"10.1016\/j.cld.2026.01.012_bib34","article-title":"Disparities in screening and risk stratification for hispanic adults with metabolic dysfunction-associated steatotic liver disease","author":"Tincopa","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2026.01.012_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12913-025-12580-5","article-title":"Implementation of a nurse-delivered, community-based liver screening and assessment program for people with metabolic dysfunction-associated steatotic liver disease (LOCATE-NAFLD trial)","volume":"25","author":"Allen","year":"2025","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"10.1016\/j.cld.2026.01.012_bib36","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/imj.16055","article-title":"Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study","volume":"53","author":"Commins","year":"2023","journal-title":"Intern Med J"},{"issue":"Supplement_1","key":"10.1016\/j.cld.2026.01.012_bib37","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa046.1522","article-title":"SUN-543 real world evidence of successful weight management for the obese population: complete reversal of obesity related metabolic co-morbidities and weight loss in patients attending a multidisciplinary weight management clinic in Australia","volume":"4","author":"Rock","year":"2020","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.cld.2026.01.012_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","article-title":"Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study","volume":"80","author":"Retat","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2026.01.012_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(24)00220-6","article-title":"Best buy interventions to address the burden of steatotic liver disease","author":"Lazarus","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.01.012_bib40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","article-title":"Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes","volume":"80","author":"D\u00edaz","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.01.012_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/nu16071030","article-title":"Effect of a low-calorie dietary intervention on liver health and body weight in adults with metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) and overweight\/obesity: a systematic review and meta-analysis","volume":"16","author":"Dobbie","year":"2024","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.cld.2026.01.012_bib42","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.01.012_bib43","article-title":"Real world evidence of successful weight management for the Obese population: complete reversal of obesity related metabolic Co-Morbidities and weight loss in patients attending a multidisciplinary weight management Clinic in Australia","volume":"4","author":"Rock","year":"2020","journal-title":"J Endo Soc"},{"key":"10.1016\/j.cld.2026.01.012_bib44","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2026.01.012_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cld.2026.01.012_bib46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2026.01.012_bib47","article-title":"Liver transplantation in Latin America: reality and challenges","volume":"28","author":"Aguirre-Villarreal","year":"2023","journal-title":"Lancet Reg Health Am"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:57:04Z","timestamp":1778878624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326126000127"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}